Testing strategy for laboratory monitoring of Hemophilia A patients treated with Emicizumab

被引：0
|
作者：
Pikta, M. [1 ]
Saks, K. [4 ]
Ross, M. [3 ]
Banys, V. [2 ]
机构：
[1] Tallinn Univ Technol, Dept Hlth Technol, Dept Lab Med, North Estonia Med Ctr, Tallinn, Estonia
[2] Vilnius Univ, Inst Biomed Sci, Dept Physiol Biochem Microbiol & Lab Med, Fac Med, Vilnius, Lithuania
[3] North Estonia Med Ctr, Dept Hematol, Tallinn, Estonia
[4] Tallinn Childrens Hosp, Dept Hematol, Tallinn, Estonia
来源：
CLINICA CHIMICA ACTA | 2022年 / 530卷
关键词：
D O I：
10.1016/j.cca.2022.04.750
中图分类号：
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号：
1001 ;
摘要：
T262
引用
收藏
页码：S186 / S186
页数：1
相关论文
共 50 条
  • [1] Laboratory Monitoring in Emicizumab-Treated Persons with Hemophilia A
    Mueller, Jens
    Pekru, Isabell
    Poetzsch, Bernd
    Berning, Beate
    Oldenburg, Johannes
    Spannagl, Michael
    THROMBOSIS AND HAEMOSTASIS, 2019, 119 (09) : 1384 - 1393
  • [2] Pharmacodynamics Monitoring of Emicizumab in Patients with Hemophilia A
    Calderara, Debora Bertaggia
    Cappelletti, Rita Marchi
    Sauvage, Ana Patricia Batista Mesquita
    Durual, Stephane
    Gomez, Francisco J.
    Zermatten, Maxime G.
    Aliotta, Alessandro
    Casini, Alessandro
    Alberio, Lorenzo
    THROMBOSIS AND HAEMOSTASIS, 2023, 123 (10) : 955 - 965
  • [3] Challenges in prophylactic therapy with Emicizumab in patients with hemophilia A: Focus on monitoring tests
    Brinza, Melen
    Uscatescu, Valentina
    Hemcinschi, Mihai
    Chiriac, Elisabeta
    Gherghe, Georgiana
    Coriu, Daniel
    REVISTA ROMANA DE MEDICINA DE LABORATOR, 2024, 32 (01): : 93 - 100
  • [4] Comparisons of global coagulation potential and bleeding episodes in emicizumab-treated hemophilia A patients and mild hemophilia A patients
    Nakajima, Yuto
    Mizumachi, Kuniyoshi
    Shimonishi, Naruto
    Furukawa, Shoko
    Yada, Koji
    Ogiwara, Kenichi
    Takeyama, Masahiro
    Shima, Midori
    Nogami, Keiji
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2022, 115 (04) : 489 - 498
  • [5] Comparisons of global coagulation potential and bleeding episodes in emicizumab-treated hemophilia A patients and mild hemophilia A patients
    Yuto Nakajima
    Kuniyoshi Mizumachi
    Naruto Shimonishi
    Shoko Furukawa
    Koji Yada
    Kenichi Ogiwara
    Masahiro Takeyama
    Midori Shima
    Keiji Nogami
    International Journal of Hematology, 2022, 115 : 489 - 498
  • [6] Laboratory response to paradigm change in hemophilia treatment How to monitor patients simultaneously treated with emicizumab and factor VIII concentrate?
    Lambert, Marjan Shafaati
    Bruzelius, Maria
    Soutari, Nida Mahmoud Hourani
    Ranta, Susanna
    Antovic, Jovan P. P.
    CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2023, 61 (12) : E248 - E250
  • [7] Evaluating the safety of emicizumab in patients with hemophilia A
    Langer, Arielle L.
    Etra, Aaron
    Aledort, Louis
    EXPERT OPINION ON DRUG SAFETY, 2018, 17 (12) : 1233 - 1237
  • [8] Usefulness of Emicizumab in Hemophilia Patients with Inhibitor
    Naga, Chiai
    Umezawa, Youtarou
    Mori, Mika
    Matsuoka, Akina
    Ashikaga, Tomoko
    Oyama, Ryo
    Keino, Dai
    Yamashita, Atsuki
    Mori, Tetsuya
    Taki, Masashi
    PEDIATRIC BLOOD & CANCER, 2018, 65 : S68 - S68
  • [9] REAL WORLD DATA ON BLEEDING PATTERN IN A COHORT OF HEMOPHILIA A PATIENTS TREATED WITH EMICIZUMAB
    Levy-Mendelovich, S.
    Brutman-Barazani, T.
    Budnik, I.
    Avishai, E.
    Barg, A. A.
    Levy, T.
    Misgav, M.
    Livnat, T.
    Kenet, G.
    HAEMOPHILIA, 2022, 28 : 83 - 84
  • [10] EVALUATION OF TWO ASSAYS FOR MONITORING EMICIZUMAB AND A THROMBIN GENERATION ASSAY IN PATIENTS WITH HEMOPHILIA A
    Vandevelde, Arne
    Crevits, Luna
    Devreese, Katrien M. J.
    INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 2023, 45 : 187 - 188
12345